PTK2 and neoplasm: Thus, FAK inhibitors that specifically address the FAK FERM domain may contribute to tumor growth prevention or inhibition, e.g., through the abrogation of nuclear-FAK-mediated degradation of the p53 tumor suppressor, which acts on p21, with the latter known as an inhibitor of cell-cycle-dependent kinases (CDKs), which are important for cell cycle progression and proliferation.